0001293971-23-000053.txt : 20231107 0001293971-23-000053.hdr.sgml : 20231107 20231107070129 ACCESSION NUMBER: 0001293971-23-000053 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231107 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231107 DATE AS OF CHANGE: 20231107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 231381499 BUSINESS ADDRESS: STREET 1: 455 GRAND UNION BOULEVARD CITY: SOMERVILLE STATE: MA ZIP: 02145 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 455 GRAND UNION BOULEVARD CITY: SOMERVILLE STATE: MA ZIP: 02145 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 8-K 1 blue-20231107.htm 8-K blue-20231107
0001293971FALSE00012939712023-11-072023-11-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________
FORM 8-K
__________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2023
__________________________
bluebird bio, Inc.
(Exact name of Registrant as Specified in Its Charter)
_____________________________________________________________
Delaware
001-35966
13-3680878
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)(IRS Employer
Identification No.)
455 Grand Union Boulevard,
Somerville, MA
02145
(Address of Principal Executive Offices)(Zip Code)
(339) 499-9300
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per shareBLUEThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 




Item 2.02
Results of Operations and Financial Condition.

On November 7, 2023, bluebird bio, Inc. (the "Company") announced its financial results for the three months ended September 30, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01
Financial Statements and Exhibits.

(d)    Exhibits

Exhibit
No.
Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 7, 2023bluebird bio, Inc.
By:/s/ Christopher Krawtschuk
Name:Christopher Krawtschuk
Title:
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer


EX-99.1 2 exhibit99120231107.htm EX-99.1 Document
image_0a.jpg
Exhibit 99.1

bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

– Continued strong commercial launch for ZYNTEGLO® and SKYSONA®; 22 patient starts across both programs to date –

– Ended quarter with $227M in cash, cash equivalents, marketable securities and restricted cash –

– Company entered into advance agreement to sell priority review voucher, if granted, for $103 million; potential non-dilutive capital would strengthen cash position –

 Management to host conference call today at 8:00AM ET 

SOMERVILLE, Mass. November 7, 2023 – bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the third quarter ended September 30, 2023, including recent commercial and operational progress, and regulatory updates.

“We continue to see strong, linear growth for both the ZYNTEGLO and SKYSONA launches, with patients completing the treatment process, and significant demand across our established qualified treatment center network," said Andrew Obenshain, chief executive officer, bluebird bio. "Launch preparations for lovo-cel for sickle cell disease are well underway in anticipation of our December 2023 PDUFA date. In the third quarter, we accelerated the growth of our QTC network, which is one hundred percent synergistic across ZYNTEGLO and lovo-cel, and advanced conversations with payers who recognize the value of lovo-cel and have responded favorably to our innovative contract offerings. We are confident in our commercial gene therapy experience, committed to continued partnership with the sickle cell community, and excited about the opportunity to bring gene therapy to individuals living with SCD.”

RECENT HIGHLIGHTS

Commercial launches of ZYNTEGLO® (betibeglogene autotemcel) and SKYSONA® (elivaldogene autotemcel)

Continued strong, linear growth for ZYNTEGLO with 16 patient starts (cell collections) since launch. Cell collection has been completed for 6 patients for SKYSONA to date.

In September, bluebird announced an amendment to its agreement with Lonza, which manufactures drug product for ZYNTEGLO and SKYSONA. The amended agreement enables increased manufacturing capacity for both therapies. The agreement also included modified payment terms intended to better align with the Company’s business objectives.

Value of ZYNTEGLO and SKYSONA continues to be recognized among commercial and government payers. Recently, bluebird signed outcomes-based agreements for ZYNTEGLO with Michigan and Massachusetts state Medicaid agencies. To date, the Company has received zero ultimate denials for both therapies and prior authorization approvals for drug product remain consistent at approximately two weeks across all payers.

bluebird’s qualified treatment center (QTC) network has scaled to 29 activated centers (defined as a signed master service agreement or MSA) including both adult and pediatric centers across


image_0a.jpg
16 states. Of these 29 activated QTCs, four have been activated to administer SKYSONA for patients with cerebral adrenoleukodystrophy (CALD) in addition to ZYNTEGLO. The Company remains on track to scale to 40-50 activated QTCs by the end of 2023.


lovo-cel FDA Review

On August 16, 2023, bluebird bio announced that the U.S. Food and Drug Administration (FDA) communicated that an advisory committee meeting will not be scheduled for lovotibeglogene autotemcel (lovo-cel).

The lovo-cel Biologics Licensing Application (BLA) review remains on track. The Agency previously accepted the lovo-cel BLA for Priority Review and set a Prescription Drug User Fee Act (PDUFA) goal date of December 20, 2023.


Advance Agreement to Sell PRV
On October 30, 2023, bluebird entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV), if received, in connection with the potential approval of lovo-cel for sickle cell disease. Under the terms of the agreement, rights to the PRV will transfer to the buyer and the Company will receive $103 million upon closing of the sale, which is contingent upon the FDA’s approval of the BLA for lovo-cel and granting of the PRV. bluebird anticipates receipt of a potential PRV should lovo-cel be approved for patients with sickle cell disease ages 12 and older. Proceeds from the potential sale of the PRV are not yet reflected in the Company’s cash runway.


Data Presentations at ASH 2023

Updated long-term follow-up data from the Company’s gene therapy programs in sickle cell disease and beta-thalassemia will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 9-12, 2023 at the San Diego Convention Center and online. bluebird continues to have the most mature gene therapy programs for both SCD and beta-thalassemia, presenting up to five years and up to nine years of long-term data, respectively.

SICKLE CELL DISEASE DATA
Oral Presentation [#1051]: Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received lovotibeglogene autotemcel (lovo-cel) Gene Therapy: Up to 60 Months of Follow-up
Presenting Author: Julie Kanter, M.D., director of the UAB Adult Sickle Cell clinic, associate professor in the Division of Hematology and Oncology, and co-director of the UAB Comprehensive Sickle Cell Disease Center at the University of Alabama in Birmingham
Date/Time: Monday, December 11, 2023, 4:30 p.m. PT

BETA-THALASSEMIA DATA
Poster Presentation [#1102]: Sustained, Efficacy, Safety, and Improved Quality of Life in Adult and Pediatric Patients with Transfusion-Dependent β-Thalassemia up to 9 Years Post Treatment with betibeglogene autotemcel (beti-cel)


image_0a.jpg
Presenting Author: Alexis A. Thompson, M.D., M.P.H., professor of pediatrics (hematology), Perelman School of Medicine, University of Pennsylvania, Philadelphia, and chief, Division of Hematology, Children’s Hospital of Philadelphia
Date/Time: Saturday, December 9, 2023, 5:30 p.m. PT

Poster Presentation [#2480]: Improvement in Iron Burden in Patients with Transfusion-Dependent β-Thalassemia (TDT) Treated with betibeglogene autotemcel (beti-cel) Gene Therapy: Up to 9 Years of Follow-up
Presenting Author: Janet L. Kwiatkowski, M.D., MSCE, professor of pediatrics (hematology), Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, and director, Thalassemia Center, Children's Hospital of Philadelphia
Date/Time: Sunday, December 10, 2023, 6:00 p.m. PT

Abstracts outlining bluebird bio’s accepted data at ASH 2023 are available on the ASH conference website.

UPCOMING ANTICIPATED MILESTONES

For lovo-cel, the FDA has set a PDUFA goal date for December 20, 2023, and if approved, the Company anticipates commercial launch in early 2024. bluebird estimates approximately 20,000 individuals living with SCD (or one-fifth of the U.S. SCD population) may be eligible for gene therapy.
The Company is on track to scale to 40-50 activated QTCs by the end of 2023. bluebird’s QTC network is designed to maximize its commercial opportunity in beta-thalassemia and to prioritize proximity to individuals with living with SCD in anticipation of a 2024 commercial launch for lovo-cel, if approved by the FDA.
For SKYSONA, the Company continues to anticipate 5-10 patient starts this year as previously guided.


THIRD QUARTER 2023 FINANCIAL RESULTS

Cash Position: The Company’s cash, cash equivalents, marketable securities and restricted cash balance was approximately $227 million, as of September 30, 2023. bluebird anticipates full-year 2023 net cash burn to be in the range of $270-$300 million, as previously guided. Based on current operating plans, bluebird expects its cash, cash equivalents and marketable securities including anticipated cash flows from operations, and excluding $53 million of restricted cash, will be sufficient to meet bluebird’s planned operating expenses and capital expenditure requirements into the second quarter of 2024.

Revenue, net: Total revenue, net was $12.4 million for the three months ended September 30, 2023, compared to $0.1 million for the three months ended September 30, 2022. The increase of $12.3 million was primarily due to SKYSONA and ZYNTEGLO product revenue.

SG&A Expenses: Selling, general and administrative expenses were $40.7 million for the three months ended September 30, 2023, compared to $33.4 million for the three months ended September 30, 2022. SG&A includes lease expense related to 50 Binney Street; however, the associated sublease income is presented in other income (expense), net. Excluding the lease


image_0a.jpg
expense for 50 Binney St., SG&A expenses were $31.1 million for the three months ended September 30, 2023, compared to $24.1 million for the three months ended September 30, 2022. This increase is mainly attributable to commercial costs driven by marketing activities for ZYNTEGLO and SKYSONA in the United States and the performance of commercial readiness activities in the United States for lovo-cel, in anticipation of potential approval, as well as increased employee compensation, benefit and other headcount-related expenses, professional fees, and information technology and facility related costs in 2023. These increased costs were partially offset by decreased consulting fees.

R&D Expenses: Research and development expenses were $45.5 million for the three months ended September 30, 2023, compared to $53.1 million for the three months ended September 30, 2022. The decrease of $7.6 million was primarily due to manufacturing costs related to SKYSONA and ZYNTEGLO now being included in inventory and cost of product revenue, as well as decreased employee compensation, benefit and other headcount-related expenses, license and milestone fees, and information technology and facility related costs in 2023. These decreased costs were partially offset by increased clinical costs, lab expenses, and consulting fees.

Net income (loss): Net loss was $71.7 million for the three months ended September 30, 2023, compared to a net loss of $76.5 million for the three months ended September 30, 2022.


CONFERENCE CALL DETAILS

bluebird will hold a conference call to discuss third quarter financial results and commercial launch progress on Tuesday, November 7 at 8:00 am ET.

To access the call via telephone, please register at this link https://register.vevent.com/register/BIee363f414c2f4fd19da314c2b328d635 to receive a dial in number and unique PIN to access the live conference call.

The live webcast of the call may be accessed by visiting the “Events & Presentations” page within the Investors & Media section of the bluebird website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird website for 90 days following the event.

About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world and is establishing the commercial model for gene therapy—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment


image_0a.jpg
to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

bluebird bio, ZYNTEGLO and SKYSONA are registered trademarks of bluebird bio, Inc. All rights reserved.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements, including our statements regarding the Company’s financial condition, results of operations, commercial revenue and key metrics, including the expected number of patient starts, and anticipated reporting and timing thereof; anticipated cash runway; the Company’s ability to obtain additional financing options to extend its cash runway; and anticipated cash burn for 2023, as well as statements regarding the Company’s plans and expectations for operations, including with respect to the therapeutic potential of the Company’s products and product candidates; the potential regulatory approval, including the PDUFA acceptance, and commercial launch of lovo-cel; closing of the sale of the Company’s PRV, if received in connection with the potential approval of lovo-cel; expectations regarding receipt of the PRV; plans to expand manufacturing capacity; anticipated growth of its QTC network and timing thereof; the Company’s ability to pursue curative gene therapies and the expected benefits for patients; and the Company’s participation in upcoming events and presentations. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect bluebird bio’s business, particularly those identified in the risk factors discussion in bluebird bio’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. These risks include, but are not limited to: delays and challenges in our commercialization and manufacturing of our products; the risk that we may not receive a Priority Review Voucher upon potential approval of lovo-cel or that lovo-cel may not be approved in the timeframe we anticipate or at all; we may encounter additional delays in the development of our programs, including the imposition of new clinical holds, that may impact our ability to meet our expected timelines and increase our costs; the internal and external costs required for our ongoing and planned activities, and the resulting impact on expense and use of cash, has been, and may in the future be, higher than expected which has caused us, and may in the future cause us to use cash more quickly than we expect or change or curtail some of our plans or both; substantial doubt exists regarding our ability to continue as a going concern; our expectations as to expenses, cash usage and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; the risk that the efficacy and safety results from our prior and ongoing clinical trials will not continue or be seen in additional patients treated with our product candidates; the risk of insertional oncogenic or other reportable events associated with lentiviral vector, drug product, or myeloablation; the risk that any one or more of our products or product candidates, including lovo-cel, will not be successfully developed, approved or commercialized, as applicable. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, bluebird bio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.


image_0a.jpg

Investors & Media

Investors:
Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com

Media:
Jess Rowlands, 857-299-6103
Jess.rowlands@bluebirdbio.com




image_0a.jpg
bluebird bio, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)


For the three months ended September 30,For the nine months ended September 30,
2023202220232022
Revenue:
Product revenue, net$    12,281$    —$    21,414$    2,739
Other revenue11171249795
Total revenues12,3927121,6633,534
Cost of product revenue10,95523,89510,056
Gross margin1,43771(2,232)(6,522)
Operating expenses:
Selling, general and administrative40,70333,402118,406106,201
Research and development45,46353,149133,881194,864
Restructuring expenses(1,699)4,940
Total operating expenses86,16684,852252,287306,005
Gain from sale of priority review voucher, net92,930
Income (loss) from operations(84,729)(84,781)(161,589)(312,527)
Interest income, net2,4543837,958663
Other income (expense), net10,5447,88530,15213,061
Income (loss) before income taxes(71,731)(76,513)(123,479)(298,803)
Income tax (expense) benefit(7)80(7)
Net income (loss)$    (71,731)$    (76,520)$    (123,399)$    (298,810)
Net income (loss) per share - basic$    (0.66)$    (0.94)$    (1.15)$    (3.91)
Net income (loss) per share - diluted$    (0.66)$    (0.94)$    (1.15)$    (3.91)
Weighted-average number of common shares used in computing net income (loss) per share - basic:
109,09881,543106,92476,361
Weighted-average number of common shares used in computing net income (loss) per share - diluted:
109,09881,543106,92476,361
Other comprehensive income (loss):
Other comprehensive income (loss), net of tax benefit (expense) of $0.0 million for the three and nine months ended September 30, 2023 and 2022
137(214)1,843(1,719)
Total other comprehensive income (loss)137(214)1,843(1,719)
Comprehensive income (loss)$    (71,594)$    (76,734)$    (121,556)$    (300,529)



image_0a.jpg
bluebird bio, Inc.
Condensed Consolidated Balance Sheet Data
(in thousands)
(unaudited)

As of
September 30,
2023
As of
December 31,
2022
Cash, cash equivalents and marketable securities$ 174,293$ 181,741
Restricted cash$ 53,022$ 45,439
Total assets    
$ 613,608$ 554,902
Total liabilities$ 391,072$ 358,559
Total stockholders’ equity$ 222,536$ 196,343



EX-101.SCH 3 blue-20231107.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 blue-20231107_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover page. Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 blue-20231107_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_0a.jpg begin 644 image_0a.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 07, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 07, 2023
Entity Registrant Name bluebird bio, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-35966
Entity Tax Identification Number 13-3680878
Entity Address, Address Line One 455 Grand Union Boulevard
Entity Address, City or Town Somerville
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02145
City Area Code 339
Local Phone Number 499-9300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol BLUE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001293971
Amendment Flag false
XML 8 blue-20231107_htm.xml IDEA: XBRL DOCUMENT 0001293971 2023-11-07 2023-11-07 0001293971 false 8-K 2023-11-07 bluebird bio, Inc. DE 001-35966 13-3680878 455 Grand Union Boulevard Somerville MA 02145 339 499-9300 false false false false Common Stock, $0.01 par value per share BLUE NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.bluebirdbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports blue-20231107.htm blue-20231107.xsd blue-20231107_lab.xml blue-20231107_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "blue-20231107.htm": { "nsprefix": "blue", "nsuri": "http://www.bluebirdbio.com/20231107", "dts": { "inline": { "local": [ "blue-20231107.htm" ] }, "schema": { "local": [ "blue-20231107.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "blue-20231107_lab.xml" ] }, "presentationLink": { "local": [ "blue-20231107_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.bluebirdbio.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blue-20231107.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blue-20231107.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001293971-23-000053-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001293971-23-000053-xbrl.zip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end